Targeting bile-acid signalling for metabolic diseases

Nature Reviews Drug Discovery

Volumn 7, Issue 8, 2008, Pages 678-693

  Thomas, Charles ^a   Pellicciari, Roberto ^b   Pruzanski, Mark ^c   Auwerx, Johan ^a,d,e   Schoonjans, Kristina ^a,e  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITY OF PERUGIA   (Italy)

^c INTERCEPT PHARMACEUTICALS   (United States)

^d INSTITUT CLINIQUE DE LA SOURIS   (France)

^e EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DIMETHOXYPHENYL) 3 (3 ETHYLVALERYL) 4 HYDROXY 6,7,8 TRIMETHOXY 2 NAPHTHOIC ACID METHYL ESTER; 3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 6 ALPHA ETHYL 23 METHYLCHENODEOXYCHOLIC ACID; 6 METHYL 2 OXO 4 THIOPHEN 2 YL 1,2,3,4 TETRAHYDROPYRIMIDINE 5 CARBOXYLIC ACID BENZYL ESTER; AGN 34; ANTILIPEMIC AGENT; AXOR 109; BILE ACID; CHENODEOXYCHOLIC ACID; CHOLIC ACID; COLESTILAN; COLESTYRAMINE; FEXARAMINE; FXR 450; GUGGULSTERONE; INT 747; OLEANOLIC ACID; S 0960; SC 435; URSODEOXYCHOLIC ACID;

ATHEROSCLEROSIS; CHOLELITHIASIS; CHRONIC DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME DEFICIENCY; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC REGULATION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BILE ACIDS AND SALTS; DRUG DELIVERY SYSTEMS; HUMANS; METABOLIC DISEASES; SIGNAL TRANSDUCTION;

EID: 48749113401     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2619     Document Type: Review

References (160)

1. Houten, S. M. & Auwerx, J. The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts. Ann. Med. 36, 482-491 (2004).
2. Ho, K. J. Circadian distribution of bile acids in the enterohepatic circulatory system in rats. Am. J. Physiol. 230, 1331-1335 (1976).
3. Engelking, L. R., Dasher, C. A. & Hirschowitz, B. I. Within-day fluctuations in serum bile-acid concentrations among normal control subjects and patients with hepatic disease. Am. J. Clin. Pathol. 73, 196-201 (1980).
4. Everson, G. T. Steady-state kinetics of serum bile acids in healthy human subjects: Single and dual isotope techniques using stable isotopes and mass spectrometry. J. Lipid Res. 28, 238-252 (1987).
5. Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137-174 (2003).
6. Schwarz, M. et al. Disruption of cholesterol 7α-hydroxylase gene in mice. II. Bile acid deficiency is overcome by induction of oxysterol 7α-hydroxylase. J. Biol. Chem. 271, 18024-18031 (1996).
7. Ishibashi, S., Schwarz, M., Frykman, P. K., Herz, J. & Russell, D. W. Disruption of cholesterol 7α-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acid and vitamin supplementation. J. Biol. Chem. 271, 18017-18023 (1996).
8. Beigneux, A., Hofmann, A. F. & Young, S. G. Human CYP7A1 deficiency: progress and enigmas. J. Clin. Invest. 110, 29-31 (2002).
9. Pullinger, C. R. et al. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110, 109-117 (2002).
10. Salen, G. Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism. Ann. Intern. Med. 75, 843-851 (1971).
11. Salen, G. & Grundy, S. M. The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis. J. Clin. Invest. 52, 2822-2835 (1973).
12. Botham, K. M. & Boyd, G. S. The metabolism of chenodeoxycholic acid to β-muricholic acid in rat liver. Eur. J. Biochem. 134, 191-196 (1983).
13. Maruyama, T. et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714-719 (2002).
14. Kawamata, Y. et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435-9440 (2003).
15. Makishima, M. et al. Identification of nuclear receptors for bile acids. Science 284, 1362-1365 (1999).
16. Parks, D. J. et al. Bile acids: Natural ligands for orphan nuclear receptors. Science 284, 1365-1368 (1999).
17. Wang, H., Chen, J., Hollister, K., Sowers, L. C. & Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3, 543-553 (1999).
18. Forman, B. M. et al. Identification of a nuclear receptor that is activated by Farnesol metabolites. Cell 81, 687-693 (1995).
19. Seol, W., Choi, H. S. & Moore, D. D. Isolation of proteins that interact specifically with retinoid X receptor: Two novel orphan receptors. Mol. Endocrinol. 9, 72-85 (1995).
20. Otte, K. et al. Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol. Cell Biol. 23, 864-872 (2003).
21. Huber, R. M. et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290, 35-43 (2002).
22. Zhang, Y., Kast-Woelbern, H. R. & Edwards, P. A. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J. Biol. Chem. 278, 104-110 (2003).
23. Zhang, Y., Castellani, L. W., Sinal, C. J., Gonzalez, F. J. & Edwards, P. A. Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 18, 157-169 (2004).
24. Mi, L. Z. et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell 11, 1093-1100 (2003).
25. Downes, M. et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11, 1079-1092 (2003).
26. Staudinger, J. L. et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl Acad. Sci. USA 98, 3369-3374 (2001).
27. Xie, W. et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl Acad. Sci. USA 98, 3375-3380 (2001).
28. Makishima, M. et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296, 1313-1316 (2002).
29. Zollner, G., Marschall, H. U., Wagner, M. & Trauner, M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 3, 231-251 (2006).
30. Eloranta, J. J. & Kullak-Ublick, G. A. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. 433, 397-412 (2005).
31. Pircher, P. C. et al. Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. 278, 27703-27711 (2003).
32. Moschetta, A., Bookout, A. L. & Mangelsdorf, D. J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nature Med. 10, 1352-1358 (2004).
33. Chiang, J. Y. Bile acid regulation of gene expression: Roles of nuclear hormone receptors. Endocr. Rev. 23, 443-463 (2002).
34. Grober, J. et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem. 274, 29749-29754 (1999).
35. Landrier, J. F., Eloranta, J. J., Vavricka, S. R. & Kullak-Ublick, G. A. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and -β genes. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G476-G485 (2006).
36. Lee, H. et al. FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. J. Lipid Res. 47, 201-214 (2006).
37. Holt, J. A. et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581-1591 (2003).
38. Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell. Metab. 2, 217-225 (2005).
39. Bavner, A., Sanyal, S., Gustafsson, J. A. & Treuter, E. Transcriptional corepression by SHP: Molecular mechanisms and physiological consequences. Trends Endocrinol. Metab. 16, 478-488 (2005).
40. Houten, S. M., Volle, D. H., Cummins, C. L., Mangelsdorf, D. J. & Auwerx, J. In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue. Mol. Endocrinol. 21, 1312-1323 (2007).
41. Foord, S. M. et al. International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol. Rev. 57, 279-288 (2005).
42. Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 484-489 (2006).
43. Vassileva, G. et al. Targeted deletion of Gpbar 1 protects mice from cholesterol gallstone formation. Biochem. J. 398, 423-430 (2006).
44. Keitel, V. et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45 695-704 (2007).
45. Katsuma, S., Hirasawa, A. & Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 329, 386-390 (2005).
46. Maruyama, T. et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J. Endocrinol. 191, 197-205 (2006).
47. Yang, J. I. et al. Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. Biochem. Biophys. Res. Commun. 361, 156-161 (2007).
48. Yasuda, H. et al. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem. Biophys. Res. Commun. 354, 154-159 (2007).
49. Lu, T. T. et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6, 507-515 (2000).
50. Goodwin, B. et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6, 517-526 (2000).
51. Brendel, C., Schoonjans, K., Botrugno, O. A., Treuter, E. & Auwerx, J. The small heterodimer partner (SHP) interacts with the Liver X receptor a, (LXRα) and represses its transcriptional activity. Mol. Endocrinol. 16, 2065-2076 (2002).
52. Mataki, C. et al. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1. Mol. Cell Biol. 27, 8330-8339 (2007).
53. Lee, Y. K. et al. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol. Endocrinol. 22, 1345-1356 (2008).
54. Stroup, D., Crestani, M. & Chiang, J. Y. Identification of a bile acid response element in the cholesterol 7 α-hydroxylase gene CYP7A. Am. J. Physiol. 273, G508-G517 (1997).
55. De Fabiani, E. et al. The negative effects of bile acids and tumor necrosis factor-α on the transcription of cholesterol 7α-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: A novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. J. Biol. Chem. 276, 30708-30716 (2001).
56. Zhang, M. & Chiang, J. Y. Transcriptional regulation of the human sterol 12α-hydroxylase gene (CYP8B1): Roles of hepatocyte nuclear factor 4α in mediating bile acid repression. J. Biol. Chem. 276, 41690-41699 (2001).
57. Inoue, Y. et al. Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4α. J. Lipid Res. 47, 215-227 (2006).
58. Choi, M. et al. Identification of a hormonal basis for gallbladder filling. Nature Med. 12, 1253-1255 (2006).
59. Ito, S. et al. Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho. J. Clin. Invest. 115, 2202-2208 (2005).
60. Goetz, R. et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell Biol. 27, 3417-3428 (2007).
61. Wu, X. et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem. 282, 29069-29072 (2007).
62. Lin, B. C., Wang, M., Blackmore, C. & Desnoyers, L. R. Liver-specific activities of FGF19 require Klotho β. J. Biol. Chem. 282, 27277-27284 (2007).
63. Goodwin, B. et al. Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-α. Mol. Endocrinol. 17, 386-394 (2003).
64. Schoenfeld, L. J. & Lachin, J. M. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: The National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann. Intern. Med. 95 257-282 (1981).
65. Leiss, O. & von Bergmann, K. Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. Scand. J. Gastroenterol. 17, 587-592 (1982).
66. Francis, G. A., Fayard, E., Picard, F. & Auwerx, J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65, 261-311 (2003).
67. Grundy, S. M., Ahrens, E. H. Jr & Salen, G. Interruption of the enterohepatic circulation of bile acids in man: Comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J. Lab. Clin. Med. 78, 94-121 (1971).
68. Nestel, P. J. & Grundy, S. M. Changes in plasma triglycericle metabolism during withdrawal of bile. Metabolism 25, 1259-1268 (1976).
69. Angelin, B., Einarsson, K., Hellstrom, K. & Leijd, B. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J. Lipid Res. 19, 1017-1024 (1978).
70. Kobayashi, M. et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56, 239-247 (2007).
71. Miller, N. E. & Nestel, P. J. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet 2, 929-931 (1974).
72. Kast, H. R. et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: A molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. 15, 1720-1728 (2001).
73. Kanaya, E., Shiraki, I & Jingami, H. The nuclear bile acid receptor FXR is activated by PGC-1α in a ligand-dependent manner. Biochem. J. 382, 913-921 (2004).
74. Stayrook, K. R. et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146, 984-991 (2005).
75. Watanabe, M. et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113 1408-1418 (2004).
76. Zhang, Y. et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl Acad. Sci. USA 103, 1006-1011 (2006).
77. Bilz, S. et al. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am. J. Physiol. Endocrinol. Metab. 290, E716-E722 (2006).
78. Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131 (2002).
79. Shimomura, I. et al. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl Acad. Sci. USA 96, 13656-13661 (1999).
80. Foretz, M., Guichard, C., Ferré, P. & Foufelle, F. Sterol regulatory element binding protein 1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc. Natl Acad. Sci. USA 96, 12737-12742 (1999).
81. Schultz, J. R. et al. Role of LXRs in control of lipogenesis. Genes Dev. 14, 2831-2838 (2000).
82. Repa, J. J. et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (i SREBP-1C) by oxysterol receptors, LXRα and LXRβ. Genes Dev. 14, 2819-2830 (2000).
83. Nishigori, H. et al. Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects. Proc. Natl Acad. Sci. USA 98, 575-580 (2001).
84. Hung., C. C. et al. Contribution of variants in the small heterodimer partner gene to birthweight, adiposity, and insulin levels: mutational analysis and association studies in multiple populations. Diabetes 52, 1288-1291 (2003).
85. Mitchell, S. M. et al. Genetic variation in the small heterodimer partner gene and young-onset type 2 diabetes, obesity, and birth weight in U.K. subjects. Diabetes 52, 1276-1279 (2003).
86. Wang, L. et al. Redundant pathways for negative feedback regulation of bile acid production. Dev. Cell 2, 721-731 (2002).
87. Kerr, T. A. et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev. Cell 2, 713-720 (2002).
88. Sinal, C. J. et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744 (2000).
89. Zhang, Y. & Edwards, P. A. FXR signaling in metabolic disease. FEBS Lett. 582, 10-18 (2008).
90. Ikemoto, S. et al. Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease. Am. J. Physiol. 273, E37-E45 (1997).
91. Sato, H. et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea Europea. Biochem. Biophys. Res. Commun. 362 793-798 (2007).
92. Tomlinson, E. et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143, 1741-1747 (2002).
93. Wang, L. et al. The orphan nuclear receptor SHP regulates PGC-1a expression and energy production in brown adipocytes. Cell. Metab. 2, 227-238 (2005).
94. Garg, A. & Grundy, S. M. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann. Intern. Med. 121, 416-422 (1994).
95. Duran-Sandoval, D. et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J. Biol. Chem. 280, 29971-29979 (2005).
96. De Fabiani, E. et al. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J. Biol. Chem. 278, 39124-39132 (2003).
97. Yamagata, K. et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxa1. J. Biol. Chem. 279, 23158-23165 (2004).
98. Ma, K., Saha, P. K., Chan, L. & Moore, D. D. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116 1102-1109 (2006).
99. Koo, S. H. et al. PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3. Nature Med. 10 530-534 (2004).
100. Cariou, B. et al. Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett. 579, 4076-4080 (2005).
101. Cariou, B. et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281, 11039-11049 (2006).
102. Han, S. I. et al. Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes. Hepatology 39, 456-463 (2004).
103. Fang, Y. et al. Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes. Hepatology 40, 961-971 (2004).
104. Dent, P. et al. Conjugated bile acids promote ERK 1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. Hepatology 42, 1291-1299 (2005).
105. Fang, Y. et al. Conjugated bile acids regulate hepatocyte glycogen synthase activity in vitro and in vivo via Gαi signaling. Mol. Pharmacol. 71, 1122-1128 (2007).
106. Auwerx, J. Improving metabolism by increasing energy expenditure. Nature Med. 12, 44-45; discussion 45 (2006).
107. Ozcan, U. et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140 (2006).
108. Fiorucci, S., Rizzo, G., Donini, A., Distrutti, E. & Santucci, L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13, 298-309 (2007).
109. Inagaki, T. et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl Acad. Sci. USA 103, 3920-3925 (2006).
110. Jiang, T. et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 56, 2485-2493 (2007).
111. Maloney, P. R. et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem. 43, 2971-2974 (2000).
112. Liu, Y. et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intraand extrahepatic cholestasis. J. Clin. Invest. 112, 1678-1687 (2003).
113. Harnish, D. C. et al. A synthetic farnesoid X receptor (FXR) agonist protects against diet-induced dyslipidemia. J. Clin. Lipidol. 1, 362 (2007).
114. Pellicciari, R., Costantino, G. & Fiorucci, S. Farnesoid X receptor: from structure to potential clinical applications. J. Med. Chem. 48, 5383-5403 (2005).
115. Cui, J. et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. 278, 10214-10220 (2003).
116. Dussault, I. et al. Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem. 278, 7027-7033 (2003).
117. Urizar, N. L. et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296, 1703-1706 (2002).
118. Wu, J. et al. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol. Endocrinol. 16 1590-1597 (2002).
119. Szapary, P. O. et al. Guggulipid for the treatment of hypercholesterolemia: A randomized controlled trial. JAMA 290 765-772 (2003).
120. Meyer, U., Costantino, G., Macchiarulo, A. & Pellicciari, R. Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study. J. Med. Chem. 48, 6948-6955 (2005).
121. Sato, H. et al. Novel potent and selective bile acid derivatives as TGR5 agonists: Biological screening, structure - activity relationships, and molecular modeling studies. J. Med. Chem. 51 1831-1841 (2008).
122. Pellicciari, R. et al. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. J. Med. Chem. 50, 4265-4268 (2007).
123. Fumio, I. et al., Receptor antagonists. WO2004067008 (2004).
124. Tsui, P. & Michalovich, D. G protein coupled receptor AXOR 109. GB2371546A (2001).
125. Yamakawa, T., Takano, T., Utsunomiya, H., Kadonosono, K. & Okamura, A. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr. J. 54, 53-58 (2007).
126. Sakamoto, S. et al. Glucuronidation converting methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4- hydroxy-6,7,8-trimethoxy-2-na phthoate (S-8921) to a potent apical sodium-dependent bile acid transporter inhibitor, resulting in a hypocholesterolemic action. J. Pharmacol. Exp. Ther. 322, 610-618 (2007).
127. Li, H. et al. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 α-hydroxylase. Metabolism 53, 927-932 (2004).
128. West, K. L., Zern, T. C., Butteiger, D. N., Keller, B. T. & Fernandez, M. L. SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs. Atherosclerosis 171, 201-210 (2003).
129. Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031 (2006).
130. Martin, F. P. et al. A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol. Syst. Biol. 3, 112 (2007).
131. Li, M. et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc. Natl Acad. Sci. USA 105, 2117-2122 (2008).
132. Libert, S. & Pletcher, S. D. Modulation of longevity by environmental sensing. Cell 131, 1231-1234 (2007).
133. Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409-1439 (2007).
134. Huang, W. et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312, 233-236 (2006).
135. Motola, D. L. et al. Identification of ligands for DAF- 12 that govern dauer formation and reproduction in C. elegans. Cell 124 1209-1223 (2006).
136. Gerisch, B. et al. A bile acid-like steroid modulates Caenorhabditis elegans lifespan through nuclear receptor signaling. Proc. Natl Acad. Sci. USA 104, 5014-5019 (2007).
137. Wang, D. Q., Tazuma, S., Cohen, D. E. & Carey, M. C. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am. J. Physiol. Gastrointest Liver Physiol. 285, G494-G502 (2003).
138. Raufman, J. P., Zimniak, P. & Bartoszko-Malik, A. Lithocholyltaurine interacts with cholinergic receptors on dispersed chief cells from guinea pig stomach. Am. J. Physiol. 274, G997-G1004 (1998).
139. Wess, J., Eglen, R. M. & Gautam, D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nature Rev. Drug Discov. 6, 721-733 (2007).
140. 3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell. Metab. 3, 449-461 (2006).
141. Le, Y., Murphy, P. M. & Wang, J. M. Formyl-peptide receptors revisited. Trends Immunol. 23, 541-548 (2002).
142. Chen, X. et al. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm. Res. 49, 744-755 (2000).
143. Podevin, P. et al. Effect of cholestasis and bile acids on interferon-induced 2′,5′-adenylate synthetase and NK cell activities. Gastroenterology 108, 1192-1198 (1995).
144. Ferrari, C., Macchiarulo, A., Costantino, G. & Pellicciari, R. Pharmacophore model for bile acids recognition by the FPR receptor. J. Comput. Aided Mol. Des. 20, 295-303 (2006).
145. 2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Mol. Cell Biol. 23, 3052-3066 (2003).
146. Kim, K. M. et al. Bile acid-mediated induction of cyclooxygenase-2 and Mcl-1 in hepatic stellate cells. Biochem. Biophys. Res. Commun. 342, 1108-1113 (2006).
147. Qiao, D., Stratagouleas, E. D. & Martinez, J. D. Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis 22, 35-41 (2001).
148. Gupta, S., Stravitz, R. T., Dent, P. & Hylemon, P. B. Down-regulation of cholesterol 7α-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J. Biol. Chem. 276, 15816-15822 (2001).
149. Stamp, D. H. Three hypotheses linking bile to carcinogenesis in the gastrointestinal tract: Certain bile salts have properties that may be used to complement chemotherapy. Med. Hypotheses 59, 398-405 (2002).
150. Pandak, W. M. et al. Expression of sterol 12α-hydroxylase alters bile acid pool composition in primary rat hepatocytes and in vivo. Gastroenterology 120, 1801-1809 (2001).
151. Li-Hawkins, J. et al. Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J. Clin. Invest, 110 1191-1200 (2002).
152. Falany C. N. et al. Molecular cloning and expression of rat liver bile acid CoA ligase. J. Lipid Res. 43, 2062-2071 (2002).
153. Shonsey, E. M. et al. Bile acid coenzyme A: Amino acid N acyltransferase in the amino acid conjugation of bile acids. Methods Enzymol. 400, 374-394 (2005).
154. He, D., Barnes, S. & Falany, C. N. Rat liver bile acid CoA:aMino acid N-acyltransferase: Expression, characterization, and peroxisomal localization. J. Lipid Res. 44, 2242-2249 (2003).
155. Meier, P. J. & Stieger, B. Bile salt transporters: Annu. Rev. Physiol. 64, 635-661 (2002).
156. Trauner, M. & Boyer, J. L. Bile salt transporters: Molecular characterization, function, and regulation. Physiol. Rev. 83 633-671 (2003).
157. Rao, A. et al. The organic solute transporter α-β, Ostα-Ostβ, is essential for intestinal bile acid transport and homeostasis. Proc. Natl Acad. Sci. USA 105, 3891-3896 (2008).
158. Modica, S. & Moschetta, A. Nuclear bile acid receptor FXR as pharmacological target: Are we there yet? FEBS Lett. 580, 5492-5499 (2006).
159. Pellicciari, R. et al. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569-3572 (2002).
160. Cai, S. Y., Xiong, L., Wray, C. G., Ballatori, N. & Boyer. J. L. The farnesoid X receptor FXRα/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R1400-R1409 (2007).